Evidence map›Paper›PMID 23577193›Full record

ArticlePloS one2013

Drosophila PRL-1 is a growth inhibitor that counteracts the function of the Src oncogene.

Krystle T Pagarigan, Bryce W Bunn, Jake Goodchild, Travis K Rahe, Julie F Weis, Leslie J Saucedo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. International journal of molecular sciences · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Krystle T PagariganDepartment of Biology, University of Puget Sound, Tacoma, Washington, USA.
Bryce W Bunn
Jake Goodchild
Travis K Rahe
Julie F Weis
Leslie J Saucedo
University of Puget Sound · US

Funding

Delineating the function of PRL-1 in Drosophila.R15CA141519 · NCI · UNIVERSITY OF PUGET SOUND · PI SAUCEDO, LESLIE · 2009 to 2009
$200k
NCI NIH HHS 1R15CA141519-01NCI NIH HHS R15 CA141519
6 · The paper itself

Abstract

Phosphatase of Regenerating Liver (PRL) family members have emerged as molecular markers that significantly correlate to the ability of many cancers to metastasize. However, contradictory cellular responses to PRL expression have been reported, including the inhibition of cell cycle progression. An obvious culprit for the discrepancy is the use of dozens of different cell lines, including many isolated from tumors or cultured cells selected for immortalization which may have missing or mutated modulators of PRL function. We created transgenic Drosophila to study the effects of PRL overexpression in a genetically controlled, organismal model. Our data support the paradigm that the normal cellular response to high levels of PRL is growth suppression and furthermore, that PRL can counter oncogenic activity of Src. The ability of PRL to inhibit growth under normal conditions is dependent on a CAAX motif that is required to localize PRL to the apical edge of the lateral membrane. However, PRL lacking the CAAX motif can still associate indiscriminately with the plasma membrane and retains its ability to inhibit Src function. We propose that PRL binds to other membrane-localized proteins that are effectors of Src or to Src itself. This first examination of PRL in a model organism demonstrates that PRL performs as a tumor suppressor and underscores the necessity of identifying the conditions that enable it to transform into an oncogene in cancer.

Indexed as

AnimalsCell MembraneCytoplasmDrosophila melanogasterDrosophila ProteinsGene Expression Regulation, DevelopmentalGenes, srcHumansProtein TransportProtein Tyrosine PhosphatasesDrosophila ProteinsPRL-1 protein, DrosophilaProtein Tyrosine Phosphatases

Identifiers

PMID23577193
PMCPMC3620046
OpenAlexW2052256809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.